^
    9d
    TAK-079-3001: A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (2025-520825-19-00)
    P2/3, N=83, Recruiting, Takeda Development Center Americas Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mezagitamab (TAK-079)
    17d
    TAK-079-3001: A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (2025-520825-19-00)
    P2/3, N=83, Not yet recruiting, Takeda Development Center Americas Inc.
    New P2/3 trial
    |
    mezagitamab (TAK-079)
    17d
    TAK-079-3002: A Study to Evaluate the Efficacy and Safety of Mezagitamab Subcutaneous Injection Compared With Placebo in Adults With Chronic Immune Thrombocytopenia (2024-514401-54-00)
    P2/3, N=77, Recruiting, Takeda Development Center Americas Inc.
    New P2/3 trial
    |
    mezagitamab (TAK-079)
    17d
    TAK-079-3003: A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune nThrombocytopenia (2025-521692-31-00)
    P2/3, N=83, Recruiting, Takeda Development Center Americas Inc.
    New P2/3 trial
    |
    mezagitamab (TAK-079)
    1m
    TAK-079-1006: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy (clinicaltrials.gov)
    P1, N=17, Completed, Takeda | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Mar 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    mezagitamab (TAK-079)
    6ms
    A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=150, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mezagitamab (TAK-079)
    7ms
    TAK-079-3001: A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (clinicaltrials.gov)
    P3, N=347, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mezagitamab (TAK-079)
    10ms
    A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (clinicaltrials.gov)
    P3, N=347, Not yet recruiting, Takeda
    New P3 trial
    |
    mezagitamab (TAK-079)
    10ms
    A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Takeda
    New P3 trial
    |
    mezagitamab (TAK-079)
    12ms
    TAK-079-3002: A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=171, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mezagitamab (TAK-079)
    1year
    A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Takeda | Trial completion date: Feb 2025 --> Mar 2026 | Trial primary completion date: Feb 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • pomalidomide • mezagitamab (TAK-079)
    1year
    A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia (clinicaltrials.gov)
    P3, N=171, Not yet recruiting, Takeda
    New P3 trial
    |
    mezagitamab (TAK-079)